Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Medicines Agency Restructures To Tackle New Challenges

Multiple Pressures Prompt ‘Future Proofing’ Exercise

Executive Summary

A restructuring involving the setting up of four new task forces is aimed at improving how the European Medicines Agency responds to issues such as permanent staff reductions and challenges in regulatory science, digital business transformation, and clinical trial strategy. 

You may also be interested in...



EMA Unveils Revamped Human Medicines Unit

Europe’s top drugs regulator has reorganized its operations to tackle what it calls “fundamental changes” brought by new legislative initiatives, digital technologies, global trends in science, and staff losses due to Brexit. More changes are to be implemented during the course of 2020 in a bid to optimize the agency’s regulatory and scientific output.

European Medicines Agency Counts The Cost Of Brexit

As the EMA settles into its permanent headquarters in Amsterdam, it hopes that new recruits will swell its depleted staff numbers. But much will depend on the necessary expertise being available, particularly following the loss of access to experts working at the UK regulator, the MHRA. 

Guido Rasi - The Face Of The EMA For A Decade

The head of the European Medicines Agency is nearing the end of his tenure. We consider Guido Rasi’s achievements over the past 10 years as well as the controversies that have arisen under his leadership – and report that sailing is likely to figure in his plans for life after the agency.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS141421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel